Phase II trial of topotecan in patients with advanced renal cell carcinoma. Academic Article uri icon

Overview

abstract

  • Fifteen patients with advanced renal cell carcinoma were treated on a phase II trial with topotecan. None of the fourteen evaluable patients achieved a complete or partial response. Myelosuppression was the most common toxicity. Eighty percent (12 of 15) of patients experienced grade III or IV neutropenia and/or anemia. Topotecan is not efficacious in the treatment of advanced renal cell carcinoma.

publication date

  • January 1, 1994

Research

keywords

  • Antineoplastic Agents
  • Camptothecin
  • Carcinoma, Renal Cell
  • Kidney Neoplasms

Identity

Scopus Document Identifier

  • 0028054333

Digital Object Identifier (DOI)

  • 10.1007/BF00874445

PubMed ID

  • 7860232

Additional Document Info

volume

  • 12

issue

  • 2